Janpix
Cambridge
About Janpix
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.7M
- Funding stage: M&A
- Last round: Series B (Oct 2020)
- Website: janpixbio.com
Industries & Categories
App Discovery, Biotechnology, Oncology, Therapeutics
Canonical: https://fsome.com/organization/janpix-1506 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.